
New Delhi, May 8 (PTI) Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at ₹198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of ₹80.4 crore on various heads, including impact of new labour code.
The company had posted a consolidated net profit of ₹459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday.
Consolidated revenue from operations in the fourth quarter was at ₹4,516.6 crore as against ₹4,417 crore in the year-ago period, it added.
Quick answers to key questions
Biocon reported a consolidated net profit of ₹198.6 crore in the fourth quarter ended March 31, FY26. This represents a 56.8% decline compared to the same period in the previous fiscal year.
Biocon's net profit decline was primarily due to an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labor code.
Biocon's consolidated revenue from operations in the fourth quarter of FY26 was ₹4,516.6 crore, a slight increase from ₹4,417 crore in the year-ago period.
Biocon's board has recommended a final dividend of 50 paise per equity share of face value of ₹5 each for the financial year ended March 31, 2026, subject to shareholder approval.
Biocon has created a unified biopharma entity by integrating its biosimilars business with its generics formulations and APIs business, aiming for a stronger balance sheet and improved leverage metrics.
Total expenses in the fourth quarter were higher at ₹4,241.2 crore as compared to ₹3,987.5 crore in the same period a year ago, it said.
The company's board has recommended a final dividend of 50 paise per equity share of face value of ₹5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said.
For FY26, consolidated net profit was at ₹368.8 crore, down from ₹1,429.4 crore in FY25, it added.
Consolidated revenue from operations in FY26 stood at ₹16,927 crore as against ₹15,261.7 crore in FY25, the company said.
"Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13 per cent YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year," Biocon Ltd Executive Chairperson Kiran Mazumdar-Shaw said.
She further said, "This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration."
Biocon has created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business, Mazumdar-Shaw said, adding the combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint.
The company said Shreehas Tambe has taken charge as CEO & Managing Director of Biocon Ltd on April 1, 2026, with Kedar Upadhye appointed as Chief Financial Officer.
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreOops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.